Abnormal concentrations of acetylated amino acids in cerebrospinal fluid in acetyl-CoA transporter deficiency.
Huppke-Brendel syndrome
SLC33A1 gene
acetyl-CoA transporter
acetylated amino acids
biomarkers
ceruloplasmin
copper
protein acetylation
Journal
Journal of inherited metabolic disease
ISSN: 1573-2665
Titre abrégé: J Inherit Metab Dis
Pays: United States
ID NLM: 7910918
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
30
07
2022
received:
27
04
2022
accepted:
20
08
2022
pubmed:
25
8
2022
medline:
10
11
2022
entrez:
24
8
2022
Statut:
ppublish
Résumé
Acetyl-CoA transporter 1 (AT-1) is a transmembrane protein which regulates influx of acetyl-CoA from the cytosol to the lumen of the endoplasmic reticulum and is therefore important for the posttranslational modification of numerous proteins. Pathological variants in the SLC33A1 gene coding for AT-1 have been linked to a disorder called Huppke-Brendel syndrome, which is characterized by congenital cataracts, hearing loss, severe developmental delay and early death. It has been described in eight patients so far, who all had the abovementioned symptoms together with low serum copper and ceruloplasmin concentrations. The link between AT-1 and low ceruloplasmin concentrations is not clear, nor is the complex pathogenesis of the disease. Here we describe a further case of Huppke-Brendel syndrome with a novel and truncating homozygous gene variant and provide novel biochemical data on N-acetylated amino acids in cerebrospinal fluid (CSF) and plasma. Our results indicate that decreased levels of many N-acetylated amino acids in CSF are a typical metabolic fingerprint for AT-1 deficiency and are potential biomarkers for the defect. As acetyl-CoA is an important substrate for protein acetylation, we performed N-terminal proteomics, but found only minor effects on this particular protein modification. The acetyl-CoA content in patient's fibroblasts was insignificantly decreased. Our data may help to better understand the mechanisms underlying the metabolic disturbances, the pathophysiology and the clinical phenotype of the disease.
Substances chimiques
Acetyl Coenzyme A
72-89-9
Ceruloplasmin
EC 1.16.3.1
Amino Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1048-1058Informations de copyright
© 2022 SSIEM.
Références
Jonas MC, Pehar M, Puglielli L. AT-1 is the ER membrane acetyl-CoA transporter and is essential for cell viability. J Cell Sci. 2010;123(19):3378-3388.
Fukuda M, Kanamori A, Nakayama J, et al. Expression cloning and characterization of a cDNA encoding a novel membrane protein required for the formation of O-acetylated ganglioside: a putative acetyl-CoA transporter. Proc Natl Acad Sci USA. 1997;94(7):2897-2902.
Farrugia MA, Puglielli L. Nε-lysine acetylation in the endoplasmic reticulum - a novel cellular mechanism that regulates proteostasis and autophagy. J Cell Sci. 2018;131(22):jcs221747. doi:10.1242/jcs.221747
Pehar M, Jonas MC, Hare TM, Puglielli L. SLC33A1/AT-1 protein regulates the induction of autophagy downstream of IRE1/XBP1 pathway. J Biol Chem. 2012;287(35):29921-29930.
Lin P, Li J, Liu Q, et al. A missense mutation in SLC33A1, which encodes the acetyl-CoA transporter, causes autosomal-dominant spastic paraplegia (SPG42). Am J Hum Genet. 2008;83(6):752-759.
Schlipf NA, Beetz C, Schüle R, et al. A total of 220 patients with autosomal dominant spastic paraplegia do not display mutations in the SLC33A1 gene (SPG42). Eur J Hum Genet. 2010;18(9):1065-1067.
Huppke P, Brendel C, Kalscheuer V, et al. Mutations in SLC33A1 cause a lethal autosomal-recessive disorder with congenital cataracts, hearing loss, and low serum copper and ceruloplasmin. Am J Hum Genet. 2012;90(1):61-68.
Horváth R, Freisinger P, Rubio R, et al. Congenital cataract, muscular hypotonia, developmental delay and sensorineural hearing loss associated with a defect in copper metabolism. J Inherit Metab Dis. 2005;28(4):479-492.
Chiplunkar S, Bindu PS, Nagappa M, et al. Huppke-Brendel syndrome in a seven months old boy with a novel 2-bp deletion in SLC33A1. Metab Brain Dis. 2016;31(5):1195-1198.
Monastiri K, Chioukh FZ, Besbes H, Hmida HB. Huppke-Brendel syndrome: two new Tunisian cases [abstract]. In: XIV international congress of inborn errors of metabolism; 2021 Nov 21-24; Sydney, Australia. J Inherit Metab Dis. 2021;44(1):273-274. Abstract nr. P-335.
Huppke P, Brendel C, Korenke GC, et al. Molecular and biochemical characterization of a unique mutation in CCS, the human copper chaperone to superoxide dismutase. Hum Mutat. 2012;33(8):1207-1215.
Liu P, Jiang B, Ma J, et al. S113R mutation in SLC33A1 leads to neurodegeneration and augmented BMP signaling in a mouse model. Dis Model Mech. 2017;10(1):53-62.
Peng Y, Li M, Clarkson BD, et al. Deficient import of acetyl-CoA into the ER lumen causes neurodegeneration and propensity to infections, inflammation, and cancer. J Neurosci. 2014;34(20):6772-6789.
Staes A, Impens F, Van Damme P, et al. Selecting protein n-terminal peptides by combined fractional diagonal chromatography. Nat Protoc. 2011;6(8):1130-1141.
Ercan AE, Techawiboonwong A, Versluis MJ, Webb AG, Ronen I. Diffusion-weighted chemical shift imaging of human brain metabolites at 7 T. Magn Reson Med. 2015;73(6):2053-2061.
Coene KLM, Kluijtmans LAJ, van der Heeft E, et al. Next-generation metabolic screening: targeted and untargeted metabolomics for the diagnosis of inborn errors of metabolism in individual patients. J Inherit Metab Dis. 2018;41(3):337-353.
Peters TMA, Engelke UFH, de Boer S, et al. Confirmation of neurometabolic diagnoses using age-dependent cerebrospinal fluid metabolomic profiles. J Inherit Metab Dis. 2020;43(5):1112-1120.
Salek RM, Steinbeck C, Viant MR, Goodacre R, Dunn WB. The role of reporting standards for metabolite annotation and identification in metabolomic studies. Gigascience. 2013;2:13. doi:10.1186/2047-217X-2-13
Helsens K, Colaert N, Barsnes H, et al. ms-lims, a simple yet powerful open source laboratory information management system for MS-driven proteomics. Proteomics. 2010;10(6):1261-1264.
Bogaert A, Fernandez E, Gevaert K. N-terminal proteoforms in human disease. Trends Biochem Sci. 2020;45(4):308-320.
Rangarh P, Kohli N. Neuroimaging findings in Menkes disease: a rare neurodegenerative disorder. BMJ Case Rep. 2018;2018:bcr2017223858. doi:10.1136/bcr-2017-223858
Tümer Z, Møller LB. Menkes disease. Eur J Hum Genet. 2010;18(5):511-518.
Petushkova NA, Zgoda VG, Pyatnitskiy MA, et al. Post-translational modifications of FDA-approved plasma biomarkers in glioblastoma samples. PLoS One. 2017;12(5):e0177427. doi:10.1371/journal.pone.0177427
Vasilyev VB. Looking for a partner: ceruloplasmin in protein-protein interactions. Biometals. 2019;32(2):195-210.
Linder MC. Ceruloplasmin and other copper binding components of blood plasma and their functions: an update. Metallomics. 2016;8(9):887-905.
Zanardi A, Conti A, Cremonesi M, et al. Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia. EMBO Mol Med. 2018;10(1):91-106.
Qu X, He Z, Qiao H, et al. Serum copper levels are associated with bone mineral density and total fracture. J Orthop Transl. 2018;14:34-44.
Shin JJ, Lee J-P, Rah J-H. Fracture in a young male patient leading to the diagnosis of Wilson's disease: a case report. J Bone Metab. 2015;22(1):33-37.
Kobayashi S, Yokoi K, Kamioka N, et al. A severe case of Menkes disease with repeated bone fracture during the neonatal period, followed by multiple arterial occlusion. Brain Dev. 2019;41(10):878-882.
Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr. 2002;22(39):439-458.
Finamore F, Priego-Capote F, Nolli S, Zufferey A, Fontana P, Sanchez JC. Characterisation of the influences of aspirin-acetylation and glycation on human plasma proteins. J Proteomics. 2015;114:125-135.
Dabek A, Wojtala M, Pirola L, Balcerczyk A. Modulation of cellular biochemistry, epigenetics and metabolomics by ketone bodies. Implications of the ketogenic diet in the physiology of the organism and pathological states. Nutrients. 2020;12(3):788. doi:10.3390/nu12030788
Wiame E, Tyteca D, Pierrot N, et al. Molecular identification of aspartate N-acetyltransferase and its mutation in hypoacetylaspartia. Biochem J. 2009;425(1):127-136.
Chakraborty G, Mekala P, Yahya D, Wu G, Ledeen RW. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J Neurochem. 2001;78(4):736-745.
Caldovic L, Tuchman M. N-acetylglutamate and its changing role through evolution. Biocehm J. 2003;372:279-290.
Thul PJ, Åkesson L, Wiking M, et al. A subcellular map of the human proteome. Science. 2017;356(6340):eaal3321. doi:10.1126/science.aal3321
Human Protein Atlas. Accessed August 13, 2021.http://www.proteinatlas.org
Ali I, Conrad RJ, Verdin E, Ott M. Lysine acetylation goes global: from epigenetics to metabolism and therapeutics. Chem Rev. 2018;118(3):1216-1252.
Drazic A, Myklebust LM, Ree R, Arnesen T. The world of protein acetylation. Biochim Biophys Acta. 2016;1864(10):1372-1401.
Ree R, Varland S, Arnesen T. Spotlight on protein N-terminal acetylation. Exp Mol Med. 2018;50(7):1-13.
Ding Y, Dellisanti CD, Ko MH, Czajkowski C, Puglielli L. The endoplasmic reticulum-based acetyltransferases, ATase1 and ATase2, associate with the oligosaccharyltransferase to acetylate correctly folded polypeptides. J Biol Chem. 2014;289(46):32044-32055.
Dieterich IA, Lawton AJ, Peng Y, et al. Acetyl-CoA flux regulates the proteome and acetyl-proteome to maintain intracellular metabolic crosstalk. Nat Commun. 2019;10(1):3929. doi:10.1038/s41467-019-11945-9
Varland S, Aksnes H, Kryuchkov F, et al. N-terminal acetylation levels are maintained during acetyl-CoA deficiency in saccharomyces cerevisiae. Mol Cell Proteomics. 2018;17(12):2309-2323.